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Supplementary Issue: Heart Failure: An Exploration of Recent Advances in Research and Treatment (A)

Abstract: Heart function fails when the organ is unable to pump blood at a rate proportional to the body’s need for oxygen or when this function leads to
elevated cardiac chamber filling pressures (cardiogenic pulmonary edema). Despite our sophisticated knowledge of heart failure, even so-called ejection fraction-preserved heart failure has high rates of mortality and morbidity. So, novel therapies are sorely needed. This review discusses current standard therapies
for heart failure and launches an exploration into emerging novel treatments on the heels of recently-approved sacubitril and ivbradine. For example, Vasoactive Intestinal Peptide (VIP) is protective of the heart, so in the absence of VIP, VIP knockout mice have dysregulation in key heart failure genes: 1) Force
Generation and Propagation; 2) Energy Production and Regulation; 3) Ca+2 Cycling; 4) Transcriptional Regulators. VIP administration leads to coronary
dilation in human subjects. In heart failure patients, VIP levels are elevated as a plausible endogenous protective effect. With the development of elastin polymers to stabilize VIP and prevent its degradation, VIP may therefore have a chance to satisfy the unmet need as a potential treatment for acute heart failure.
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Introduction

Heart function fails when the organ is unable to pump
blood at a rate proportional to the body’s need for oxygen
or when this function leads to elevated cardiac chamber
filling pressures (cardiogenic pulmonary edema). Despite
our sophisticated knowledge of heart failure, even the socalled ejection fraction–preserved heart failure has high
rates or mortality and morbidity. So, novel therapies are
sorely needed. With over a million hospitalizations annually – up 175% over the past 25 years – and costs of nearly
$15.4 billion dollars, acute heart failure is a critically
important health concern. Furthermore, half of the patients
discharged from the hospital are readmitted within half-ayear. In-hospital mortality remains high between 4% and
7%.1,2 Heart failure is a significant problem as the population ages. The prevalence is 2.5% of the US population or
5 million patients (from the National Health and Nutrition Education Survey). 2
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Common etiological mechanisms of heart failure include
coronary ischemia, valvular disease, hypertension, and
diastolic dysfunction. Yet, other causes include: postpartum
cardiomyopathy; postinfectious, chronic tachycardia; metabolic
dysregulation; adverse medication side effects (particularly adriamycin chemotherapy); orphan disease Duchenne’s muscular
dystrophy; infiltrative diseases (such as amyloidosis); and inflammatory/connective tissue diseases (such as systemic lupus erythematosus). When known causes of heart failure are excluded, then
heart failure is classified as idiopathic. Less often studied versus
chronic heart failure, acute decompensated heart failure is associated with abrupt-onset symptoms associated with hospitalization.
Nearly half of the admitted patients with heart failure have preserved ejection fraction.2,3
In order to appreciate the physiology of heart failure, a review
of fundamental principles is on order. The Frank–Starling Law
states that the stroke volume of the heart increases in response
to an increase in the volume of blood filling the heart (the end
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diastolic volume) when all other factors remain constant. The
increased volume of blood stretches the ventricular wall, causing
cardiac muscle to contract more forcefully (the so-called Frank–
Starling mechanism). The stroke volume may also increase as a
result of greater contractility of the cardiac muscle during exercise,
independent of the end-diastolic volume. The Frank–Starling
mechanism appears to make its greatest contribution to increasing stroke volume at lower work rates, and contractility has its
greatest influence at higher work rates.4
While the Frank–Starling mechanism may contribute at
lower work rates, cardiac injury at lower work rates may activate
additional mechanisms. Cardiac injury in heart failure leads to
not only reduced left ventricular (LV) dysfunction but also activation of the renin angiotensin system and sympathetic nervous
system, ultimately causing LV thickening, remodeling, vasoconstriction (with pulmonary hypertension and cell dysregulation),
and, possibly, apoptosis or programmed cell death. This sequence
culminates in clinical heart failure – with attendant mortality
and morbidity. Severity is graded by the New York Heart Association Class, with increasing severity of classes I to IV. Another
grading system is the American Heart Association Staging
System with stage C, classified as the symptomatic stage. This
stage C is a result of known structural heart diseases and is associated with shortness of breath, fatigue, and reduced exercise
tolerance. The obvious goal is to prevent progressive LV dysfunction to end-stage D, resulting in LV assist device implantation, cardiac transplant, or palliative care.5

Current Standard Therapies

Medication management of acute heart failure often entails
diuretics to reduce preload, vasodilators to reduce preload
and/or afterload, and inotropes to augment contractility.
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) and aldosterone antagonists
also aim to reduce preload and afterload.6 One adverse side
effect (usually nonallergic antibody, non-IgE–mediated) of
ACE inhibitors is angioedema (risk up to 15.5%). The risk
of angioedema from ARBs is 4.4%. For ACE inhibitors, this
angioedema results from increased bradykinin production,
which can occur at any time while taking these medications
due to interruption of the conversion of angiotensin I to
angiotensin II. Angioedema from ACE inhibitors and ARBs
may lead to life-threatening swelling of the throat, requiring critical interventions, ie, intubation or tracheostomy. For
ARBs, the mechanism of action of angioedema is not due to
direct production of bradykinin and is unclear. Some chronic
persistent angioedema may occur despite cessation of these
medications. Some evidence suggests that treatment with
a bradykinin B2 receptor blocker (icatibant) may attenuate
angioedema attacks early.7–9 Patients with hereditary angioedema (deficiency of C1 esterase inhibitor) and spontaneous
attacks of swelling should not take ACE inhibitors. Clearly, it
would be prudent to design a heart failure drug that does not
incur risk of angioedema.
58
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Other medications used for heart failure include inotropes –
such as dopamine and dobutamine. While inotropes increase
cardiac output, they often do so at the expense of increasing
myocardial oxygen demand, predisposition to arrhythmias, and
neurohormonal activation. Some patients may need invasive
monitoring. Furthermore, inotropes do not improve mortality.
There is 50% survival at 6 months and nearly 100% mortality
at 1 year for those heart failure patients who are dependent
on inotropes.10
Long-term survival among heart failure patients may be
improved with β-blockers,11 ACE inhibitors,12 aldosterone
antagonists,13 electrophysiology devices such as automatic
implantable cardiovascular defibrillators, and vasodilators.
Other drugs such as digoxin and diuretics do not alter death
rates – digoxin reduces hospitalizations, while diuretics (furosemide or lasix) improve symptoms.
Another aspect of heart failure is diastolic dysfunction
with preserved LV ejection fraction, accounting for half of
the hospitalizations. Pathophysiologically, there is concentric
remodeling and increased LV end diastolic pressure from a
stiff left ventricle, thereby preventing relaxation. Medications
for diastolic dysfunction are similar to systolic dysfunction:
ACE inhibitors, ARBs, diuretics, and β-blockers.14

Emerging Novel Therapies

LCZ696. In August of 2014, the first new drug for heart
failure in many years, called LCZ696, was shown to prevent
deaths and hospitalizations in heart failure patients – better
than the gold standard enalipril, which is an ACE inhibitor. In
the PARADIGN-HF study, LCZ696, which is comprised of
two drugs – an ARB and a neprilysin inhibitor called sacubitril
– reduced the risk of cardiovascular-related death to 13.3%,
versus the ACE inhibitor cohort rate of 16.5%. This use of sacubitril is an example of utilizing new or different pathways to
treat heart failure.15
Sacubitril is a prodrug that is activated to LBQ657 by
de-ethylation via esterases.16 LBQ657 inhibits the enzyme
neprilysin,17 which is responsible for the degradation of atrial
and brain natriuretic peptide, two blood pressure–lowering
peptides that work mainly by reducing blood volume. As a
result of reduced degradation of helpful peptides, these heart
failure patients on sacubitril have less circulating blood volume and have done well in terms of prevention of deaths and
hospitalizations (supra vide).
Ivabradine. On April 15, 2015, the Food and Drug Admini
stration approved Corlanor (ivabradine) to reduce hospitalizations from worsening heart failure. The indications for ivabradine
are specific: symptoms of heart failure that are stable and a normal heartbeat with a resting heart rate of at least 70 beats per
minute and patients must already be taking β-blockers at the
highest dose they can tolerate. Ivabradine is thought to work by
decreasing heart rate and represents the first approved product in
this drug class. It works via the If (funny channel) and does not
affect other cardiac ionic currents (not beta receptor mediated).

Novel therapies for heart failure

Heart rate lowering with ivabradine reduces myocardial oxygen
demand, simultaneously improving oxygen supply. There are no
negative inotropic or lusitropic (myocardial relaxation) effects
from ivabradine. Ventricular contractility is preserved.18 In clinical
trials of 6,505 participants, hospitalizations for heart failure were
reduced compared to placebo. The most notable side effects were
bradycardia, hypertension, atrial fibrillation, and temporary visual
disturbance entailing seeing flashes of light. The bradycardia may
be severe.19
Vasoactive intestinal peptide. Other novel therapeutic
agents for heart failure may consequently have plausible efficacy on the heels of sacubitril and ivabradine. For example,
Vasoactive intestinal peptide (VIP), discovered by Drs Sami I.
Said and Victor Mutt in the 1970s, is a 28–amino acid peptide found in nerve terminals and in mast cells.20 VIP increases
cyclic adenosine monophosphate (cAMP) intracellularly to
cause cardiac contraction in an analogous fashion to glucagon.21
VIP also is a smooth muscle relaxant, which may be beneficial
in pulmonary hypertension associated with heart failure22 and
VIP inhibits the proliferation of smooth muscle cells, attenuating vascular remodeling.23
Inasmuch as sometimes vascular remodeling is a compensatory mechanism for dysfunction in heart failure, VIP has
promise to treat this deleterious component. Enhanced peripheral vascular tone is a major factor in determining deterioration
of clinical heart failure. Nakamura has reviewed peripheral
circulatory failure in heart failure and notes that it is caused
“not only by simple arterial muscle constriction, but also by
structural and functional changes, including receptor and postreceptor levels in the vasculature.” Thus, vascular remodeling
potentially may be an important mechanism underlying vasodilatory failure in both limb conduit and intraskeletal muscle

vessels, contributing significantly to LV dysfunction and exercise intolerance in patients with heart failure.24
What is compelling about VIP as a novel therapeutic
agent for heart failure is evident in mice lacking the gene for
VIP. These mice have dilated cardiomyopathy. Human heart
failure gene programs are overexpressed in VIP knockout
mice.25 So, the plausibility of VIP as both a treatment for
heart failure in patients and a modifier of one’s biology in a
pharmacogenomic fashion may have traction.
Four categories of genes triggering heart failure are
increased in mice without heart-protective VIP: (1) force generation and propagation; (2) energy production and regulation; (3) Ca2+ cycling; and (4) transcriptional regulators. Force
generation gene mutations encoding proteins of the muscle
sarcomere have been associated with both hypertrophic and
dilated cardiomyopathy. Overexpression of sarcomere protein
expression in the setting of a dilated cardiomyopathy26 may
suggest a compensatory mechanism. Upregulated expression of
other force generation genes such as sarcoglycan and caveolin27 in VIP knockout mice supports the concept of increased
force to the extracellular matrix, with ventricular hypertrophy, for apparent release of protein products of these genes in
heart failure.
Regarding energy production and regulation genes, it has
been increasingly recognized that nuclear-encoded metabolic
gene mutations are key regulators of hypertrophic cardiac
remodeling and heart failure. For example, mutations in genes
encoding the lysosome-associated membrane protein are associated with heart failure in patients.28 In the absence of VIP
in VIP knockout (KO) mice, upregulation of PRKAG2, for
example,29 would support a compensatory response to thinning
of the cardiac wall. Another category of gene program alteration

Table 1. Gene alterations related to hypertrophic/dilated cardiomyopathy in VIP KO mice compared to wild-type (WT) mice.
Gene symbol

Gene name

KO/WT (fold change)

P value

Description

casq1

calsequestrin 1

19

0.004

casq2

calsequestrin 2

2

0.050

Calsequestrin is a major modulator of Ca2+ released from the
sarcoplasmic reticulum. Overexpression of these proteins
induces cellular hypertrophy in cardiac myocytes.39,40

ttn

Titin (connectin)

10

0.004

Loss of titin homeostasis in cardiomyocytes results in
myocardial stiffness observed in patients with hypertensive
heart failure and a preserved ejection fraction.41

cd59a

cd59a

3.4

0.002

cd59b

cd59b

1.5

0.007

CD59 proteins regulate assembly of the membrane attack
complex. Loss of function for both CD59a and CD59b variants
result in a hemolytic phenotype.42 Elevated levels of expression may result as a molecular response to prolong erythrocyte longevity and improve oxygen distribution in the setting of
heart failure.

lum

lumican

3.3

0.010

“Lumican is increased in experimental and clinical heart
failure, and its production by cardiac fibroblasts is induced by
mechanical and proinflammatory stimuli.”43

TPM1

alpha
tropomyosine

2.9

0.008

Mutations that lead to dysregulation of this thin filament protein
are associated with hypertrophic cardiomyopathies.44,45

DES

desmin

2.9

0.024

Upregulated in various forms of human heart failure.46

ACTC1

Cardiac actin

1.6

0.070

Mutations of cardiac thin filament proteins eg, ACTC1 result in
hypertrophic cardiomyopathy, particularly LV hypertrophy.47,48

Note: Heart failure–related genes are upregulated in VIP knockout mice. 26
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– Ca2+ cycling – is critically important, since protein and RNA
levels of key calcium modulators are altered in acquired and
inherited forms of heart failure.
Overexpression of FKBP30 in mice supports the concept
that these mice would have aberrant excessive release of calcium during the relaxation/diastolic phase of the cardiac cycle,
enhancing the opportunity to generate hypertrophy. Cardiac
hypertrophy is attenuated in murine models with overexpression
of Caveolin-3, a potent upstream inhibitor of T-type Ca2+
current,18 and rats treated with Calhex231, an inhibitor of
calcium-sensing receptor.31 Similarly, deleterious LV hypertrophy may therefore plausibly be suppressed with exogenous
RV hypertrophy
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Figure 1. VIP knockout mice have progressive right ventricular
hypertrophy with age. 25 Wild-type control is the left-most bar labeled WT.

VIP administration. The fourth category of genetic alteration
is transcriptional regulators. Mechanisms which activate or
repress cardiac gene transcription may induce key molecules,
which directly or indirectly lead to cardiac remodeling. Lack
of VIP in VIP KO mice with the phenotype of biventricular
dilated cardiomyopathy and primary pulmonary hypertension
is concurrent with strong overexpression of cardiac muscle
genes, supporting the concept of VIP in vivo as a maestro
conductor maintaining homeostasis of the heart.26
Table 1 shows on the next page multiple heart failure
gene programs which are overexpressed in VIP KO mice.
An accompanying bar chart (Fig. 1) in blue demonstrates
progressive right ventricular hypertrophy in these mice with
age. MicroMRI (Fig. 2) additionally shows right ventricular
dilation in VIP KO mice. These physiological abnormalities
are associated with premature death compared to the wild
type (Fig. 3). Compensatory and pathogenic gene programs
are displayed in Figure 4, with overexpression of leptin as a
compensatory reaction for cardiac cachexia and low body weight
along with proinflammatory interleukin-6 (IL-6) and IL-1.
VIP signal transduction is shown in Figure 6. VIP increases
intracellular cAMP and acts via protein kinase A to activate
transcriptional promoters.32,33 VIP upregulates IL-10, which
is anti-inflammatory.34
Kupari et al found that VIP levels in serum from healthy
subjects and patients with aortic stenosis and heart failure were released into the coronary sinus. VIP levels were
higher in heart failure patients. These authors concluded
that, although VIP was marginally elevated systemically in
heart failure, it is the major neuroendocrine contributor to

Figure 2. Right ventricular dilation is present in VIP knockout mice, with large areas of the RV shown in red approaching the size of the left ventricle. 26
These are end-diastolic multislice microMRI images acquired in the coronal plane orientation (short-axis view). A control mouse heart is shown in the top
panels and a VIP−/− mouse heart is shown in the bottom panels.
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Kaplan–meier survival estimates
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Figure 3. Severely increased mortality is seen in VIP KO mice compared
to wild-type. 25 The cause of death was not determined. However, as
shown in Figure 1, there is an association of progressive right ventricular
hypertrophy with age.
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0.50
35
30
25
20
15
10

heart failure.35 Smitherman infused VIP into the left coronary artery of four other men at four levels. The maximum
decline in coronary vascular resistance was 46% and was not
associated with an increase in myocardial oxygen uptake.
He concluded that “1) intravenous administration of low to
intermediate doses of VIP in humans is associated with subKO/WT
3.00
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Figure 5. Scatter gram of RV ED volumes measured in the short-axis
magnetic resonance images of individual control mice (blue) and VIP KO
mice (red circles) demonstrating that the RV phenotype varied in the VIP
KO mice. Right ventricular end diastolic volume is higher in some VIP KO
mice, suggesting diastolic dysfunction. 26

2.82

2.50

1.00

5

KO/WT

Figure 4. For gene microarray analyses, RNA was isolated from
lung samples of five male VIP KO and five WT mice and subjected to
Affymetrix gene profiling (Expression Analysis, Durham, NC, USA).
Overexpression of leptin gene in VIP KO mice may be a function of
compensation for the “cardiac cachexia” leading to low body weight
and lack of subcutaneous adipocytes. There is also overexpression of
proinflammatory genes such as IL-6 and IL-1a. 26

stantial coronary vasodilation, 2) the coronary bed appears to
be at least as responsive as other vascular beds, 3) the coronary
vasodilation is due to both direct and indirect effects, and
4) the coronary vasodilation does not appear to be mediated
by prostaglandins.”36,37
So, the potential of an exogenous, sustainable VIP drug
would be to help relax coronary arteries. Lucia et al also
found that VIP plasma levels were higher in heart failure
patients with dilated cardiomyopathy compared to healthy
subjects and was higher in older subjects. Heart failure
patients with higher New York Heart Association seve
rity had lower levels of VIP. These data support a putative
restorative role of VIP in treating disease. These data also
suggest that heart failure patients with worse disease have
an inability to produce VIP. The capacity of the elderly to
produce VIP is heartening, so that low levels are not due to
aging itself. 38
PhaseBio Corporation recently conducted a phase 1,
single ascending dose (SAD) study in patients with essential
hypertension. PB1046 was administered subcutaneously and
was found to be well-tolerated and demonstrated a prolonged,
dose-dependent effect on blood pressure, which was used as a
biomarker for activity in this study. (See http://clinicaltrials.
gov/ct2/show/NCT01523067 for further details.)
With this demonstration of safety and tolerability at
efficacious doses, PhaseBio conducted a second phase 1
Clinical Medicine Insights: Cardiology 2015:9(S2)
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Figure 6. VIP is recognized by three different G-protein–coupled receptors: pituitary adenylate cyclase-activating peptide receptor (PAC1), vasoactive
intestinal peptide receptor 1 (VPAC1) and vasoactive intestinal peptide receptor 2 (VPAC2).49 These receptors share a common signal transduction
pathway in which activation of adenylyl cyclase (AC) upregulates cAMP production and subsequently activates protein kinase A (PKA).50–52 Downstream
effects of PKA activation regulate cardiovascular function.53–60

SAD study in patients with essential hypertension, with
the product administered intravenously to support the use
of PB1046 in an acute setting (http://clinicaltrials.gov/
show/NCT01873885). Subsequent phase 2 clinical studies will examine the efficacy of multiple ascending doses of
PB1046 in patients with pulmonary arterial hypertension
and heart failure.

Conclusion

Current therapies do not control progression of heart failure well and must often be used in combinations to optimize
62
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results. Novel emerging therapies show promise with improved
outcomes but many still have limitations. LCZ696 utilizes a
novel pathway to treat heart failure and improves mortality in
comparison to the current standard of care, enalipril. It is important to remember that as a combination therapy utilizing an
ARB, it carries a risk of inducing life-threatening angioedema.
Ivabradine reduces rates of heart failure–related hospitalization,
but the indications for use are strict and this medication carries
undesirable side effects that potentiate etiologic mechanisms
of heart failure. VIP, an endogenous peptide, shows widespread
cardiovascular benefits as a vasodilator, an attenuator of smooth

Novel therapies for heart failure

muscle proliferation, and a homeostatic regulator of heart failure gene programs thereby preventing hypertrophy of cardiac
myocytes. Endogenous levels of VIP have been shown to be elevated in certain stages of heart failure. However, later stages of
the disease show significantly diminished levels. Administration
of exogenous VIP in early and late stages of heart failure may
provide the most benefit for patients. Further research is warranted. Use of an elastin polymer to protect and stabilize VIP
as a therapeutic agent shows the interface between engineering
and medicine, and it bodes well for the influence of technology
on society, particularly since heart failure will continue to grow
as a prevalent problem as the population ages. VIP may therefore have a chance to satisfy the unmet need as a treatment for
acute heart failure, thus fulfilling discoverer Dr Sami I. Said’s
dream to promote human health.
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